Tumor microenvironment and immunotherapy for triple-negative breast cancer

Tumor microenvironment and immunotherapy for triple-negative breast cancer

Abstract Triple-negative breast cancer (TNBC) is a subtype of breast cancer known for its high aggressiveness and poor prognosis. Conventional treatment of TNBC is challenging due to its heterogeneity and lack of clear targets. Recent advancements in immunotherapy have shown promise in treating TNBC...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zijie Guo, Ziyu Zhu, Xixi Lin, Shenkangle Wang, Yihong Wen, Linbo Wang, Lili Zhi, Jichun Zhou
Format:	Article
Language:	English
Published:	BMC 2024-12-01
Series:	Biomarker Research
Subjects:	Triple-negative breast cancer (TNBC) Immunotherapy Tumor microenvironment (TME) Immune checkpoint Cancer treatment protocols Biomarkers
Online Access:	https://doi.org/10.1186/s40364-024-00714-6
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study
by: Huayan Gu, et al.
Published: (2025-02-01)

Targeting NANOS1 in triple-negative breast cancer: synergistic effects of digoxin and PD-1 inhibitors in modulating the tumor immune microenvironment
by: Tangyi Wang, et al.
Published: (2025-01-01)

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
by: Liubov A. Tashireva, et al.
Published: (2025-01-01)

The potential benefits of radiotherapy in elderly patients with early-stage triple-negative breast cancer
by: Zheng Xu, et al.
Published: (2025-01-01)

Construction of the bromodomain-containing protein-associated prognostic model in triple-negative breast cancer
by: Wei Chen, et al.
Published: (2025-01-01)

Function of vasohibin-2 and the mechanism of alternative splicing in triple-negative breast cancer
by: WANG Wei, et al.
Published: (2024-12-01)

A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment
by: Zixuan Xiong, et al.
Published: (2025-02-01)

The interplay between persistent pathogen infections with tumor microenvironment and immunotherapy in cancer
by: Si Chen, et al.
Published: (2024-09-01)

Exploring the role of metabolic pathways in TNBC immunotherapy: insights from single-cell and spatial transcriptomics
by: Shi-liang Chen, et al.
Published: (2025-01-01)

Interleukin-12 Inhibits Tumor Growth and Metastasis Promoted by Tumor-Associated Mesenchymal Stem Cells in Triple-Negative Breast Cancer
by: Babak Jahangiri, et al.
Published: (2024-09-01)

Editorial: Tertiary lymphoid structures (TLS) in the tumor immune microenvironment
by: Xinbo Gao, et al.
Published: (2025-01-01)

Functionalized biomimetic nanoparticles loaded with salvianolic acid B for synergistic targeted triple-negative breast cancer treatment
by: Nuo Cheng, et al.
Published: (2025-02-01)

The role of ferroptosis in colorectal cancer and its potential synergy with immunotherapy
by: Wenhua Xia, et al.
Published: (2025-01-01)

Network pharmacological analysis and in vitro testing of the rutin effects on triple-negative breast cancer
by: Chang Cheng, et al.
Published: (2025-01-01)

RSL3 induces ferroptosis by activating the NF-κB signalling pathway to enhance the chemosensitivity of triple-negative breast cancer cells to paclitaxel
by: Jialin Yuan, et al.
Published: (2025-01-01)

Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer
by: Beatriz Ramos, et al.
Published: (2025-02-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Immunotherapy in Recurrent Ovarian Cancer
by: Keyao Chen, et al.
Published: (2025-01-01)

Investigation of survival and prognostic factors in triple negative molecular subtype male breast cancer patients: A population-based study
by: Ahmet Necati Sanli, et al.
Published: (2024-04-01)

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01)

Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis
by: Qi Xu, et al.
Published: (2024-10-01)

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities
by: Wen-yu Cai, et al.
Published: (2025-02-01)

Integrative pan-cancer analysis and experiment validation identified GLS as a biomarker in tumor progression, prognosis, immune microenvironment, and immunotherapy
by: Dongming Li, et al.
Published: (2025-01-01)

The microenvironment cell index is a novel indicator for the prognosis and therapeutic regimen selection of cancers
by: Xian-Yan Yang, et al.
Published: (2025-01-01)

ITGA4 as a potential prognostic and immunotherapeutic biomarker in human cancer and its clinical significance in gastric cancer: an integrated analysis and validation
by: Jiaxing Zhang, et al.
Published: (2025-02-01)

Multiomics analysis reveals the involvement of NET1 in tumour immune regulation and malignant progression
by: Jian Pang, et al.
Published: (2025-01-01)

Triple-negative breast cancer patients treated with subcutaneous mastectomy with immediate reconstruction: single institution experience
by: Artur Bocian, et al.
Published: (2024-12-01)

Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II
by: Junjiang Fu, et al.
Published: (2025-01-01)

Deep Learning and Radiomics in Triple-Negative Breast Cancer: Predicting Long-Term Prognosis and Clinical Outcomes
by: Cheng C, et al.
Published: (2025-01-01)

Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk
by: Xinyu Ren, et al.
Published: (2025-04-01)

Platycodon grandiflorum-derived extracellular vesicles suppress triple-negative breast cancer growth by reversing the immunosuppressive tumor microenvironment and modulating the gut microbiota
by: Min Yang, et al.
Published: (2025-02-01)

Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy
by: Shuyan He, et al.
Published: (2025-01-01)

Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer
by: Bohan Ning, et al.
Published: (2025-01-01)

Classifications of triple-negative breast cancer: insights and current therapeutic approaches
by: Ziqi Chen, et al.
Published: (2025-02-01)

The value of inflammation-related indicators in chemotherapy efficacy and disease-free survival of triple-negative breast cancer
by: Jie Zhu, et al.
Published: (2025-02-01)

Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints
by: Yunyan Dai, et al.
Published: (2025-01-01)

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
by: Man Wang, et al.
Published: (2025-01-01)

AXL: shapers of tumor progression and immunosuppressive microenvironments
by: Yihui Liu, et al.
Published: (2025-01-01)

Viral Transcript and Tumor Immune Microenvironment-Based Transcriptomic Profiling of HPV-Associated Head and Neck Squamous Cell Carcinoma Identifies Subtypes Associated with Prognosis
by: Anastasiia Nikitina, et al.
Published: (2024-12-01)

Galectin-3 secreted by triple-negative breast cancer cells regulates T cell function
by: Annat Raiter, et al.
Published: (2025-02-01)